PMC:6019327 / 693185-693562 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6019327","sourcedb":"PMC","sourceid":"6019327","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6019327","text":" JACC 2013; 61: 1894-1903390 2013 Randomized to RF ablation or pharmacological rate control 52 Persistent AF (100%), EF 22% abl, 25% rate control PVI, optional linear abl and CFAEs 12 months Change in peak O2 consumption (also reported single procedure off drug ablation success) Peak O2 consumption increase greater with abl, 72% abl success 0.018 15% Not reported","divisions":[{"label":"td","span":{"begin":0,"end":28}},{"label":"td","span":{"begin":30,"end":34}},{"label":"td","span":{"begin":36,"end":93}},{"label":"td","span":{"begin":95,"end":97}},{"label":"td","span":{"begin":99,"end":149}},{"label":"td","span":{"begin":151,"end":185}},{"label":"td","span":{"begin":187,"end":196}},{"label":"td","span":{"begin":198,"end":286}},{"label":"td","span":{"begin":288,"end":350}},{"label":"td","span":{"begin":353,"end":358}},{"label":"td","span":{"begin":360,"end":363}}],"tracks":[]}